-
Xtalpi Partners with JW Pharmaceutical to Enhance Drug Discovery with AI
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., a global leader in AI-powered drug discovery, has announced a multi-million RMB strategic partnership with South Korea’s leading pharmaceutical company, JW Pharmaceutical (KRX: 001060). The collaboration aims to integrate AI and automation into drug discovery, enhancing JW Pharmaceutical’s development efficiency,…
-
JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma
•
China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for its JWATM204 in patients with advanced hepatocellular carcinoma (HCC). This first-in-human study aims to evaluate the safety, tolerability, dose-limiting toxicity, and pharmacokinetic profile of JWATM204 in adult subjects with advanced HCC. It will also explore…
